^
    10d
    Primary Myelofibrosis (PMF)-The German ONKOPEDIA Guideline 2025. (PubMed, Int J Cancer)
    In recent years, oral therapy with the JAK1/2 inhibitor ruxolitinib has become the standard of care. Since 2021, the JAK2/FLT3 inhibitor fedratinib has also been approved in the EU (note: in Switzerland, fedratinib will no longer be available as of February 28, 2025, as Swissmedic did not extend its time-limited approval)...Compared to the other two JAK inhibitors, momelotinib is particularly effective in patients with clinically symptomatic moderate to severe anemia. Results from studies investigating additional JAK inhibitors, combination therapies, and novel agents have also demonstrated significant efficacy and point toward future therapeutic developments, although these approaches are not yet available for routine clinical practice.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • ACVR1 (Activin A Receptor Type 1)
    |
    Jakafi (ruxolitinib) • Inrebic (fedratinib) • Ojjaara (momelotinib)
    21d
    A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=20, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation • FLT3 mutation
    |
    Xospata (gilteritinib) • Ojjaara (momelotinib)
    1m
    Interferon-primed immune landscapes predict immune-related adverse events during immune checkpoint inhibitor therapy. (PubMed, Front Cell Dev Biol)
    Perturbation-based screening identified multiple compounds capable of reversing these interferon-amplified signatures, and in vitro experiments demonstrated that alpinetin and momelotinib suppress interferon-γ signaling through distinct STAT1-and JAK-STAT-dependent mechanisms. irAEs may arise from the convergence of pre-existing myeloid inflammation and interferon-driven lymphocyte activation before therapy. Our study provides a predictive framework for identifying high-risk patients and highlights mechanistically grounded compounds for potential irAE mitigation.
    Journal • Adverse events • Checkpoint inhibition • IO biomarker
    |
    IFNG (Interferon, gamma) • STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    Ojjaara (momelotinib)
    2ms
    Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study. (PubMed, Cancer)
    Momelotinib demonstrated meaningful clinical benefit and acceptable safety in cytopenic patients pretreated with ruxolitinib, which supports its role after ruxolitinib failure.
    Retrospective data • Journal • Real-world evidence
    |
    JAK2 (Janus kinase 2) • JAK1 (Janus Kinase 1) • ACVR1 (Activin A Receptor Type 1)
    |
    Jakafi (ruxolitinib) • Ojjaara (momelotinib)
    2ms
    Targeted treatment of anemia in Myelofibrosis and the impact of jak inhibitors. (PubMed, Expert Opin Pharmacother)
    Unmet needs include standardized endpoints, biologically stratified trials, and validation of hemoglobin and transfusion responses as markers. Strategies like momelotinib plus luspatercept, earlier intervention, and new molecular therapies could turn treatment from palliation to durable control and disease modification.
    Review • Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    Xpovio (selinexor) • Reblozyl (luspatercept-aamt) • Ojjaara (momelotinib) • pelabresib (DAK539) • elritercept (KER-050)
    2ms
    ATLAS: A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome (clinicaltrials.gov)
    P2/3, N=192, Not yet recruiting, GlaxoSmithKline
    New P2/3 trial
    |
    Ojjaara (momelotinib)
    2ms
    A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms (clinicaltrials.gov)
    P1, N=220, Recruiting, Janssen Research & Development, LLC | N=53 --> 220
    Enrollment change • First-in-human • CALR
    |
    CALR (Calreticulin)
    |
    Jakafi (ruxolitinib) • Ojjaara (momelotinib)
    2ms
    A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P2, N=80, Recruiting, GlaxoSmithKline | N=56 --> 80
    Enrollment change
    |
    Ojjaara (momelotinib)
    2ms
    A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P2, N=80, Recruiting, GlaxoSmithKline | N=59 --> 80 | Trial completion date: Mar 2029 --> Dec 2027
    Enrollment change • Trial completion date
    |
    Ojjaara (momelotinib)
    2ms
    Comparison of the enzymatic and cellular profiles of clinical JAK inhibitors for the treatment of myelofibrosis. (PubMed, Blood Neoplasia)
    In conclusion, ruxolitinib was the most potent, and selective JAKinib with no relevant effects in JAK2-independent cells. In contrast, fedratinib, pacritinib, and momelotinib inhibited many other kinases and inhibited cell growth by JAK2-unrelated mechanisms at clinically relevant concentrations.
    Journal
    |
    ACVR1 (Activin A Receptor Type 1)
    |
    Jakafi (ruxolitinib) • Vonjo (pacritinib) • Inrebic (fedratinib) • Ojjaara (momelotinib)
    2ms
    ODYSSEY: Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis (clinicaltrials.gov)
    P2, N=68, Recruiting, GlaxoSmithKline | Trial completion date: Nov 2026 --> Mar 2028 | Trial primary completion date: Oct 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Reblozyl (luspatercept-aamt) • Ojjaara (momelotinib)
    3ms
    A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P2, N=59, Recruiting, GlaxoSmithKline | N=45 --> 59
    Enrollment change
    |
    Ojjaara (momelotinib)